Serum Levels of Natriuretic Peptides in Children before and after Treatment for an Atrial Septal Defect, a Patent Ductus Arteriosus, and a Coarctation of the Aorta—A Prospective Study

Table 2

Serum levels of ANPN and NT-proBNP in patients measured at baseline and at 6 and 12 months’ follow-up, and in controls. Values are expressed as median (range).

	N	ANPN (nmol/L)	NT-proBNP (ng/L)
		Median (range)	Median (range)
Controls	76	0.30 (0.10–3.70)	68 (14–3224)
Controls	64	0.28 (0.10–0.61)	57 (14–157)
>0.5 year
ASD	21	0.44^§ (0.15–1.40)	79^§ (11–245)
baseline
ASD	20	0.40^§ (0.17–0.71)	96^§ (17–202)
6 months
ASD	21	0.31^† (0.10–0.70)	58 (17–260)
1 year
PDA	25	0.37^§ (0.21–1.21)	141^§ (36–974)
baseline
PDA	25	0.37^§† (0.14–0.58)	71^§† (21–228)
6 months
CoA	15	0.60^§ (0.16–16.30)	128 (5–35001)
baseline
CoA	15	0.46^§† (0.09–1.20)	86^§† (9–441)
6 months
CoA	13	0.34^† (0.09–0.82)	60^† (32–309)
12 months

ANPN: N-terminal proatriopeptide; ASD: atrial septal defect; CoA: coarctation of the aorta;
Mos: months; NT-proBNP: N-terminal probrain natriuretic peptide; PDA: patent ductus arteriosus;
^§𝑃<.05 as compared with control group > 0.5 years except CoA group at baseline is compared with whole control group;
^†𝑃<.05 as compared with baseline.